Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Salmanton-García, J; Hoenigl, M; Salzer, HJF; Lackner, M; Prattes, J; Dichtl, K; Winkler-Zamani, M; Krause, R; Stemler, J; Lass-Flörl, C; Cornely, OA; Willinger, B.
The Austrian landscape of diagnostic capacity and access to treatment for invasive fungal infections.
Mycoses. 2023; 66(12):1056-1063
Doi: 10.1111/myc.13650
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Dichtl Karl
- Hönigl Martin
- Krause Robert
- Prattes Jürgen
- Salzer Helmut J. F.
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- INTRODUCTION: Immunosuppression after chemotherapy, stem cell transplantation or solid organ transplantation are the main risk factors for invasive fungal infections in Austria. Here, we aim to describe the status of laboratory mycology and the access to antifungal treatment in Austria. METHODS: Between October and November 2021, hospitals were contacted to participate in our online survey: www.clinicalsurveys.net/uc/IFI_management_capacity/. Centres were required to provide information on their institutional profile; self-assessment of burden of invasive fungal infections; access to microscopy, culture, serology, antigen detection and molecular testing; and availability of antifungal agents and therapeutic drug monitoring. RESULTS: Responses were collected from university hospitals and laboratories in Graz, Innsbruck, Linz and Vienna. The four hospitals can provide tertiary care and were highly specialised, including management of patients with severe immunosuppression. All sites consider the incidence of invasive fungal infections to be moderate. Access to microscopy, culture, serology, antigen detection and molecular testing is provided regardless of laboratory. The maximum capacity to identify fungi varies from institution to institution. All currently marketed antifungal agents are available at the four sites. CONCLUSION: Austria is currently well equipped to deal with the emerging threat of invasive fungal infections. However, hospitals may consider preparing for the potential endemicity of certain infections in the near future.
- Find related publications in this database (using NLM MeSH Indexing)
- Humans - administration & dosage
- Antifungal Agents - therapeutic use
- Austria - epidemiology
- Invasive Fungal Infections - diagnosis, drug therapy, epidemiology
- Fungi - administration & dosage
- Health Services Accessibility - administration & dosage
- Find related publications in this database (Keywords)
- antifungal agents
- antigen test
- antifungal susceptibility
- antimycotic chemotherapy
- deep fungal infection
- fungemia
- microdilution
- PCR